AriBio is focused on developing innovative therapies for neurodegenerative diseases through its proprietary platform known as ARIDD™. This platform integrates artificial intelligence with reverse engineering and a comprehensive approach to drug development, allowing for the identification and creation of multi-mechanism therapies. By leveraging AI, AriBio aims to enhance the drug discovery process, making it more efficient and effective in addressing complex neurodegenerative conditions.

In addition to its ARIDD™ platform, AriBio emphasizes open innovation as a key component of its strategy. This approach encourages collaboration and knowledge sharing, which can accelerate the development of new treatments. The company is actively advancing its pipeline, as evidenced by recent milestones such as receiving IND approval from China's NMPA and authorization for Phase 3 clinical trials from the EMA, showcasing its commitment to pioneering solutions in the field of neurodegenerative diseases.

South Korea

AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.

AriBio

Company Details